Project Grant R01EY036042
- Summary The National Eye Institute (NEI), under its Vision Research program (CFDA 93.867), awarded $417,162 to the University of Houston System for a two-year project (July 1, 2025 – June 30, 2027) investigating the birefringence properties of the lamina cribrosa and posterior eye structures as they relate to glaucoma detection and diagnosis. The project addresses a critical clinical need by developing advanced optical imaging methodologies to detect early structural and stress-related changes...
- The National Eye Institute (NEI), through its Vision Research federal grant program (CFDA 93.867), awarded a $661,635 project grant to The Research Foundation For The State University Of New York, doing business as SUNY Downstate Health Sciences University, to conduct research on elucidating the molecular changes in the extracellular matrix of the outflow pathway that regulate outflow facility in steroid-induced ocular hypertension and open-angle glaucoma. This 4-year project aims to determine...
- Federal Grant Award Summary The National Eye Institute (NEI), under its Vision Research program (CFDA 93.867), awarded a $764,881 Project Grant to the University of Colorado-Denver on September 15, 2025, to investigate the role of advanced glycation end products (AGEs) in primary open angle glaucoma (POAG). Primary open angle glaucoma is the most common form of glaucoma, accounting for approximately 80% of all glaucoma cases globally and affecting 80 million people, with 11 million...
- Federal Grant Award Summary The University of Alabama at Birmingham received a $636,862 Project Grant from the National Eye Institute's Vision Research program (CFDA 93.867) effective April 1, 2026, through March 31, 2030. This research initiative focuses on developing and validating mechanical, vascular, and morphometric biomarkers to assess individual eye-specific susceptibility to glaucoma onset and progression. The project will deliver longitudinal optical coherence tomography (OCT)...
- Federal Grant Award Summary Emory University received a $617,201 Project Grant from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) effective July 1, 2025, through March 31, 2030. The award supports research to understand axonal injury mechanisms in glaucomatous optic neuropathy by leveraging innovative tools from engineering, artificial intelligence (AI), and advanced imaging techniques, specifically optical coherence tomography (OCT). The research aims to...
- This Project Grant award from the National Eye Institute (NEI) under the Vision Research (CFDA 93.867) program is providing $438,018 to Emory University to investigate the impact of age, sex, and menopause on scleral biomechanics and gene expression related to glaucoma risk. The 2-year project aims to measure scleral mechanical properties and assess gene expression profiles in a rat model across young, older adult, and surgically menopausal groups. This research aims to provide functional and...
- This $460,625 Project Grant was awarded by the National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) to Yale University. The grant will fund research to investigate the cellular and synaptic mechanisms underlying changes in retinal ganglion cell (RGC) activity following optic nerve injuries in mouse models of glaucoma. Specifically, the project aims to (1) determine the underlying mechanisms for altered RGC activity after increased intraocular pressure or...
- Federal Grant Award Summary Baylor College of Medicine received a $1,093,095 Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research program) effective July 1, 2025 through March 31, 2030, to investigate the role of vascular ligands and neurovascular dysfunction in glaucoma pathogenesis and to identify therapeutic targets for neuroprotection. The research leverages an innovative ligandomics technology platform to globally map cell-binding ligands with binding...
- Federal Project Grant Award Summary The National Eye Institute (NEI) awarded The Schepens Eye Research Institute, Inc. a Project Grant of $545,948 under the Vision Research program (CFDA 93.867) to advance understanding of glaucoma pathophysiology. The award, effective April 1, 2026 through March 31, 2030, supports research investigating the role of reactive astrocytes in glaucoma progression and retinal ganglion cell (RGC) survival. The research aims to move beyond traditional neurocentric...
- Federal Grant Award Summary The National Eye Institute (NEI) awarded $427,625 under the Vision Research program (CFDA 93.867) to The Washington University for a two-year project (April 1, 2026 – March 31, 2028) to develop novel statistical methodologies for detecting and characterizing visual field progression in primary open-angle glaucoma (POAG). The primary deliverables include: (1) a change-point statistical model integrating longitudinal mean deviation measures to identify early disease...
BIOMECHANICS OF THE HUMAN OPTIC NERVE HEAD FOR GLAUCOMA BIOMARKERS. - SUMMARY GLAUCOMA IS A LEADING CAUSE OF BLINDNESS IN THE UNITED STATES AND WORLDWIDE. THE DISEASE IS CHARACTERIZED BY THE DEATH OF RETINAL GANGLION CELLS AFTER THE INITIAL INJURY TO THEIR AXONS IN THE OPTIC NERVE HEAD AND BY EXTENSIVE CHANGES IN THE STRUCTURE OF THE CONNECTIVE TISSUES OF THE OPTIC NERVE HEAD. THERE IS CONSENSUS THAT THE INTRAOCULAR PRESSURE GENERATES A BIOMECHANICAL RESPONSE IN THE TISSUES OF THE OPTIC NERVE HEAD THAT IS FUNDAMENTAL TO THE DEVELOPMENT OF GLAUCOMA AXON DAMAGE. MECHANICAL DEFORMATION AND REMODELING OF THE OPTIC NERVE HEAD IN RESPONSE TO A LONG-TERM IOP ELEVATION CAN DAMAGE THE RETINAL GANGLION CELL AXONS BOTH DIRECTLY AND INDIRECTLY THROUGH MECHANICAL ACTIVATION OF THE ASTROCYTES AND LAMINA CRIBROCYTES AND DISRUPTION OF BLOOD FLOW FROM THE DISTORTION OF BLOOD VESSELS. THE CELLS OF THE OPTIC NERVE HEAD CAN ALSO REACT TO CHANGES IN THE MECHANICAL PROPERTIES OF THE CONNECTIVE TISSUE STRUCTURES OF THE OPTIC NERVE HEAD IN WAYS THAT COMPROMISE THE PHYSIOLOGICAL SUPPORT FOR THE AXONS. THE SCIENTIFIC PREMISE OF THE PROPOSED STUDY IS THAT BIOMECHANICAL BEHAVIORS AND PROPERTIES OF THE TISSUES OF THE OPTIC NERVE HEAD WILL PREDICT THE RISK OF AXON INJURY IN OPEN ANGLE GLAUCOMA. IN AIM 1, WE WILL IMAGE THE EYES OF HUMAN SUBJECTS WITH PRIMARY OPEN ANGLE GLAUCOMA AT DIFFERENT STAGES USING AN OPTICAL IMAGING METHOD CALLED SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY. IMAGES WILL BE ACQUIRED BEFORE AND AFTER A CHANGE IN THE INTRAOCULAR PRESSURE TO MEASURE THE DEFORMATION USING DIGITAL VOLUME CORRELATION. THE IOP WILL BE CHANGED BY LASER SUTURE LYSIS AS PART OF THE POST-OPERATIVE CARE OF PATIENTS WHO HAVE HAD RECENT TRABECULECTOMY SURGERY AND BY STARTING OR STOPPING GLAUCOMA MEDICATION. IN AIM 2, WE WILL DEVELOP PATIENT-SPECIFIC FINITE ELEMENT MODELS. THE MODELS WILL BE USED TO ANALYZE THE DEFORMATIONS MEASURED IN AIM 1 TO DETERMINE THE PATIENT-SPECIFIC MECHANICAL PROPERTIES OF THE TISSUES OF THE OPTIC NERVE HEAD. THE MECHANICAL PROPERTIES AND STRAINS WILL BE ANALYZED TO DETERMINE HOW THEY VARY WITH AGE, SEX, RACE, STAGE OF GLAUCOMA DAMAGE, AND THE RATE OF PAST PROGRESSION. IN AIM 3, WE WILL ANALYZE THE OUTCOMES IN AIMS 1 AND 2 TO IDENTIFY POTENTIAL BIOMECHANICAL MARKERS FOR PROSPECTIVE LONGITUDINAL STUDIES TO EVALUATE THE ABILITY OF THE BIOMECHANICAL MARKERS TO PREDICT GLAUCOMA PROGRESSION. WE WILL ALSO REIMAGE THE EYES OF PARTICIPATING PATIENTS TO MEASURE REMODELING TO THE STRUCTURE AND MECHANICAL PROPERTIES OF THE OPTIC NERVE HEAD. THESE STUDIES WILL DETERMINE WHETHER THE DEFORMATIONS AND MATERIAL PROPERTIES OF THE TISSUES OF THE OPTIC NERVE HEAD, MEASURED BY CURRENT IMAGING, IMAGE ANALYSIS AND MODELING METHODS, ARE PREDICTIVE OF GLAUCOMA PROGRESSION AND ENHANCE FUNDAMENTAL UNDERSTANDING OF HOW THE TISSUES REMODEL IN OPEN ANGLE GLAUCOMA.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $409.4k | 8/8/25 | ||
| Not listed | $409.4k | 6/7/24 |